Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
ATM
Final classification
VUS
ATM c.7875T>G · p.Asp2625Glu
ATM

NM_000051.4:c.7875T>G (p.Asp2625Glu) is a missense variant in exon 53 of ATM, observed at extremely low frequency in gnomAD v4.1 (AF = 6.82 × 10⁻⁶, 11/1,613,262 alleles), meeting PM2_Supporting.

Gene
ATM
Transcript
NM_000051.4
HGVS · transcript:coding
NM_000051.4:c.7875T>G
Consequence
N/A
GRCh38
chr11:108332848 T>G
GRCh37
chr11:108203575 T>G
Basis Richards et.al., 2015 - Combining rules v1.5.0 criteria-combination framework was evaluated deterministically with applied criteria: PM2 supporting; no rule matched the adjudicated criteria.
Richards et.al., 2015 - Combining rules v1.5.0 criteria-combination framework was evaluated deterministically with applied criteria: PM2 supporting; no rule matched the adjudicated criteria.
Classification rationale
PM2 VUS
ATM c.7875T>G

NM_000051.4:c.7875T>G (p.Asp2625Glu) is a missense variant in exon 53 of ATM, observed at extremely low frequency in gnomAD v4.1 (AF = 6.82 × 10⁻⁶, 11/1,613,262 alleles), meeting PM2_Supporting.1 In silico predictions are inconclusive: REVEL score (0.373) falls between the VCEP PP3 threshold (>0.7333) and BP4 threshold (≤0.249), and SpliceAI predicts no splicing impact (max delta = 0.07).2 The variant is classified as 'Functional' (High confidence) in the ATM SNV combined-score table (PMID 40580951), reflecting in silico composite prediction rather than experimental functional data; no variant-specific functional assays are available.3 ClinVar reports this variant as Pathogenic (1 submitter, criteria provided, single submitter); however, the VCEP does not use PP5/BP6, and no independent case-level or functional evidence corroborates this classification.4 With only PM2_Supporting met and no other criteria satisfied, this variant does not reach a Likely Pathogenic or Likely Benign classification under the ACMG/AMP combination rules and is classified as a Variant of Uncertain Significance.5

PM2 VUS
3 vcep_suppl_tables1_pmid_40580951
5 generic_acmg_combination_rules
Gene diagram · NM_000051.4 · variants mapped to exon structure
ATM NM_000051.4
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 10 assessed
Applied · 1
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
NM_000051.4:c.7875T>G is present in gnomAD v4.1 at an allele frequency of 6.82 × 10⁻⁶ (0.00068%; 11/1,613,262 alleles), which is below the ATM VCEP PM2_Supporting threshold of ≤0.001%. The variant is absent from gnomAD-Canada and observed at 3.99 × 10⁻⁶ in gnomAD v2.1 (1/250,866 alleles).
gnomAD v4.1 AF = 6.82e-06 (≤0.001% threshold met)grpmax FAF = 5e-06. Absent from gnomAD-Canada.
Assessed · not applied
Pathogenic
PS1 PS1 requires a different nucleotide change resulting in the same amino acid substitution (p.Asp2625Glu) with a prior pathogenic or likely pathogenic classification.
PS3 No variant-specific experimental functional assay data are available.
PS4 No case-control studies demonstrating significantly increased prevalence of NM_000051.4:c.7875T>G in affected individuals compared to controls are available.
PP1 No co-segregation data are available for NM_000051.4:c.7875T>G.
PP3 REVEL score is 0.373, below the ATM VCEP PP3 threshold of >0.7333.
Benign
BA1 gnomAD v4.1 grpmax filtering AF is 5 × 10⁻⁶ (0.0005%), well below the ATM VCEP BA1 threshold of >0.5%.
BS1 gnomAD v4.1 grpmax filtering AF is 5 × 10⁻⁶ (0.0005%), well below the ATM VCEP BS1 threshold of >0.05%.
BS3 No variant-specific experimental functional studies demonstrating normal protein function or rescue of ATM-specific features are available.
BP2 No evidence of NM_000051.4:c.7875T>G occurring in trans with a pathogenic or likely pathogenic ATM variant in an unaffected individual aged ≥18 years.
BP4 REVEL score is 0.373, above the ATM VCEP BP4 threshold of ≤0.249 for missense variants.
N/A · 14 PVS1 · PS2 · PM1 · PM5 · PM6 · PP2 · PP4 · PP5 · BS2 · BS4 · BP1 · BP5 · BP6 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 6.81848e-06; MAF= 0.00068%, 11/1613262 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 9.32436e-06; MAF= 0.00093%, 11/1179706 alleles, homozygotes = 0); grpmax FAF= 5e-06.
v2.1
This variant is present in gnomAD v2.1 (AF= 3.98619e-06; MAF= 0.00040%, 1/250866 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 8.81663e-06; MAF= 0.00088%, 1/113422 alleles, homozygotes = 0).
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.00068% · 11 / 1,613,262
0 hom · FAF 0.0005%
European (non-Finnish)
11 / 1,179,706
0.00093%
+ 9 not observed (Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
0.0004% · 1 / 250,866
0 hom
European (non-Finnish)
1 / 113,422
0.00088%
+ 7 not observed (African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian)
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Pathogenic (1 clinical laboratory). (ClinVarID = 802788)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.07). REVEL score = 0.373. BayesDel score = -0.137386.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
9Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 4 PMIDs not cited in assessment
20301317 ↗ Hereditary Ataxia Overview. CLINVAR
20301790 ↗ Ataxia-Telangiectasia. CLINVAR
24418350 ↗ EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. CLINVAR
20050888 ↗ EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias. CLINVAR